PomegraRevvity Stock Jumps 12% After Q3 Earnings Beat
Why did Revvity stock jump 12%?
Revvity (RVTY) stock rose 12% to $169.99 on Tuesday after a third-quarter earnings beat and a raised 2026 profit forecast of $5.40–$5.45 a share, as sales grew faster than expected.
Key numbers
| Stock close (Nov 3) | $169.99+12.1% from $151.60 |
|---|---|
| Adjusted EPS | $1.37vs $1.30 expected |
| Revenue | $728.9Mvs ~$698M expected |
| 2026 EPS outlook | $5.40–$5.45from $5.30–$5.40 |
| Organic growth | 7%life sciences +9% |
| Free cash flow | $152M99% of adjusted profit |
What happened
Revvity (RVTY) stock rose 12% to $169.99 on Tuesday after a third-quarter earnings beat and a raised 2026 profit forecast of $5.40–$5.45 a share, as sales grew faster than expected. Adjusted profit was $1.37 a share, against the $1.30 analysts expected. Sales reached $728.9 million, about $30 million above forecasts. Growth that strips out currency swings and deals (organic growth) was 7%, led by 9% in its life sciences business, which sells lab tools to drug and biotech researchers. The earlier 2026 profit forecast was $5.30–$5.40 a share.
Why it matters
Revvity's report suggests spending by drug and biotech researchers may be recovering, something lab-tool makers have been waiting for. When a company raises its own forecast (guidance), investors often read it as a sign management expects stronger months ahead. The stock is up about 73% this year after the jump, per one source, so expectations are now higher.
Who this affects
- MarketbullishMedium impact
- Lab-tool investors gain as a key demand signal improves.
- CompanybullishHigh impact
- Revvity shareholders gain; the stock hit a 52-week high.
- CompetitorsbullishLow impact
- Waters and Thermo Fisher also lifted forecasts, helping the group.
- IndustrybullishMedium impact
- Lab demand from drugmakers looks steadier, which helps suppliers.
Revvity vs Waters, Thermo Fisher
How we got here
Revvity reports Q3 results and lifts 2026 EPS outlook to $5.40–$5.45.
Shares close at $169.99, up from $151.60, a new 52-week high.
What to watch
- Whether the Diagnostics business, up 5% organically, keeps improving.Q4 2026
- Fourth-quarter results and Revvity's first look at 2027.Q1 2027
Educational content only. Not investment advice.
More briefsAll briefs →
Yum Brands Stock Slips 0.2% Despite Earnings Beat
Yum Brands (YUM) beat Q3 profit forecasts at $1.56 vs $1.49, but Taco Bell sales fell 4% after an outbreak.
Drax Shares Jump 8% After $27B AI Data Center Plan
Drax (DRX.L) traded at 878.75p as Brookfield plans a 1-gigawatt campus at its Yorkshire power station
Fiserv Stock Jumps 12% After Earnings Beat and Buyback
Fiserv (FISV) closed at $58.40 as it doubled its savings goal to $1B and said underlying sales stopped falling